This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care
The safety profile was described as manageable, though not without notable toxicities
Subscribe To Our Newsletter & Stay Updated
